Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/50315
Type
ArticleCopyright
Open access
Collections
- IOC - Artigos de Periódicos [12973]
Metadata
Show full item record37
CITATIONS
37
Total citations
16
Recent citations
5.98
Field Citation Ratio
2.81
Relative Citation Ratio
THE POTENTIAL INVOLVEMENT OF P2X7 RECEPTOR IN COVID-19 PATHOGENESIS: A NEW THERAPEUTIC TARGET?
Affilliation
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Toxoplasmose e outras Protozooses. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Toxoplasmose e outras Protozooses. Rio de Janeiro, RJ, Brasil
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Toxoplasmose e outras Protozooses. Rio de Janeiro, RJ, Brasil
Abstract
Coronavirus disease 2019 (COVID-19) pathogenesis remains under investigation. Growing evidence indicates the establishment of a hyperinflammatory response, characterized by sustained production of cytokines, such as IL-1β. The release and maturation of this cytokine are dependent on the activation of a catalytic multiprotein complex, known as “inflammasome”. The most investigated is the NLRP3 inflammasome, which can be activated by various stimuli, such as the recognition of extracellular ATP by the P2X7 receptor. Based on the recent literature, we present evidence that supports the idea that the P2X7R/NLRP3 axis may be involved in the immune dysregulation caused by the SARS-CoV-2 infection.
Share